Oliver Wirths, Christina Lehnen, Merle Fricke, Ivan Talucci, Hans-Wolfgang Klafki, Barbara Morgado, Sandra Lehmann, Carolina Münch, Thomas Liepold, Jens Wiltfang, Agueda Rostagno, Jorge Ghiso, Hans Michael Maric, Olaf Jahn, Sascha Weggen
{"title":"氨基酸末端拉长的 Aβ 肽由分泌型金属蛋白酶 ADAMTS4 生成,并沉积在阿尔茨海默氏症患者的大脑中。","authors":"Oliver Wirths, Christina Lehnen, Merle Fricke, Ivan Talucci, Hans-Wolfgang Klafki, Barbara Morgado, Sandra Lehmann, Carolina Münch, Thomas Liepold, Jens Wiltfang, Agueda Rostagno, Jorge Ghiso, Hans Michael Maric, Olaf Jahn, Sascha Weggen","doi":"10.1111/nan.12991","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The aggregation and deposition of amyloid-β (Aβ) peptides in the brain is thought to be the initial driver in the pathogenesis of Alzheimer's disease (AD). Aside from full-length Aβ peptides starting with an aspartate residue in position 1, both N-terminally truncated and elongated Aβ peptides are produced by various proteases from the amyloid precursor protein (APP) and have been detected in brain tissues and body fluids. Recently, we demonstrated that the particularly abundant N-terminally truncated Aβ4-x peptides are generated by ADAMTS4, a secreted metalloprotease that is exclusively expressed in the oligodendrocyte cell population. In this study, we investigated whether ADAMTS4 might also be involved in the generation of N-terminally elongated Aβ peptides.</p><p><strong>Methods: </strong>We used cell-free and cell-based assays in combination with matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF) and electrochemiluminescence sandwich immunoassays to identify and quantify N-terminally elongated Aβ peptide variants. Antibodies against these Aβ variants were characterised by peptide microarrays and employed for the immunohistochemical analyses of human brain samples.</p><p><strong>Results: </strong>In this study, we discovered additional ADAMTS4 cleavage sites in APP. These were located N-terminal to Asp-(1) in the Aβ peptide sequence between residues Glu-(-7) and Ile-(-6) as well as Glu-(-4) and Val-(-3), resulting in the release of N-terminally elongated Aβ-6-x and Aβ-3-x peptides, of which the latter serve as a component in a promising Aβ-based plasma biomarker. Aβ-6/-3-40 peptides were detected in supernatants of various cell lines and in the cerebrospinal fluid (CSF), and ADAMTS4 enzyme activity promoted the release of Aβ-6/-3-x peptides. Furthermore, by immunohistochemistry, a subset of AD cases displayed evidence of extracellular and vascular localization of N-terminally elongated Aβ-6/-3-x peptides.</p><p><strong>Discussion: </strong>The current findings implicate ADAMTS4 in both the pathological process of Aβ peptide aggregation and in the early detection of amyloid pathology in AD.</p>","PeriodicalId":19151,"journal":{"name":"Neuropathology and Applied Neurobiology","volume":"50 3","pages":"e12991"},"PeriodicalIF":4.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Amino-terminally elongated Aβ peptides are generated by the secreted metalloprotease ADAMTS4 and deposit in a subset of Alzheimer's disease brains.\",\"authors\":\"Oliver Wirths, Christina Lehnen, Merle Fricke, Ivan Talucci, Hans-Wolfgang Klafki, Barbara Morgado, Sandra Lehmann, Carolina Münch, Thomas Liepold, Jens Wiltfang, Agueda Rostagno, Jorge Ghiso, Hans Michael Maric, Olaf Jahn, Sascha Weggen\",\"doi\":\"10.1111/nan.12991\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>The aggregation and deposition of amyloid-β (Aβ) peptides in the brain is thought to be the initial driver in the pathogenesis of Alzheimer's disease (AD). Aside from full-length Aβ peptides starting with an aspartate residue in position 1, both N-terminally truncated and elongated Aβ peptides are produced by various proteases from the amyloid precursor protein (APP) and have been detected in brain tissues and body fluids. Recently, we demonstrated that the particularly abundant N-terminally truncated Aβ4-x peptides are generated by ADAMTS4, a secreted metalloprotease that is exclusively expressed in the oligodendrocyte cell population. In this study, we investigated whether ADAMTS4 might also be involved in the generation of N-terminally elongated Aβ peptides.</p><p><strong>Methods: </strong>We used cell-free and cell-based assays in combination with matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF) and electrochemiluminescence sandwich immunoassays to identify and quantify N-terminally elongated Aβ peptide variants. Antibodies against these Aβ variants were characterised by peptide microarrays and employed for the immunohistochemical analyses of human brain samples.</p><p><strong>Results: </strong>In this study, we discovered additional ADAMTS4 cleavage sites in APP. These were located N-terminal to Asp-(1) in the Aβ peptide sequence between residues Glu-(-7) and Ile-(-6) as well as Glu-(-4) and Val-(-3), resulting in the release of N-terminally elongated Aβ-6-x and Aβ-3-x peptides, of which the latter serve as a component in a promising Aβ-based plasma biomarker. Aβ-6/-3-40 peptides were detected in supernatants of various cell lines and in the cerebrospinal fluid (CSF), and ADAMTS4 enzyme activity promoted the release of Aβ-6/-3-x peptides. Furthermore, by immunohistochemistry, a subset of AD cases displayed evidence of extracellular and vascular localization of N-terminally elongated Aβ-6/-3-x peptides.</p><p><strong>Discussion: </strong>The current findings implicate ADAMTS4 in both the pathological process of Aβ peptide aggregation and in the early detection of amyloid pathology in AD.</p>\",\"PeriodicalId\":19151,\"journal\":{\"name\":\"Neuropathology and Applied Neurobiology\",\"volume\":\"50 3\",\"pages\":\"e12991\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuropathology and Applied Neurobiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/nan.12991\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropathology and Applied Neurobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/nan.12991","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:淀粉样蛋白-β(Aβ)肽在大脑中的聚集和沉积被认为是阿尔茨海默病(AD)发病机制的最初驱动因素。除了以第 1 位天冬氨酸残基为起始位的全长 Aβ 肽外,淀粉样前体蛋白(APP)的各种蛋白酶还可产生 N 端截短和拉长的 Aβ 肽,并在脑组织和体液中检测到它们。最近,我们证明了特别丰富的 N 端截短的 Aβ4-x 肽是由 ADAMTS4 生成的,ADAMTS4 是一种分泌型金属蛋白酶,只在少突胶质细胞群中表达。在这项研究中,我们探讨了 ADAMTS4 是否也可能参与生成 N 端拉长的 Aβ 肽:方法:我们使用无细胞和基于细胞的检测方法,结合基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF)和电化学发光夹心免疫测定法来鉴定和量化 N 端拉长的 Aβ 肽变体。针对这些Aβ变体的抗体通过肽微阵列进行表征,并用于人脑样本的免疫组化分析:结果:在这项研究中,我们发现了 APP 中额外的 ADAMTS4 裂解位点。这些位点位于Aβ肽序列中Asp-(1)的N端,介于Glu-(-7)和Ile-(-6)残基以及Glu-(-4)和Val-(-3)残基之间,从而释放出N端拉长的Aβ-6-x和Aβ-3-x肽,后者是一种很有前景的基于Aβ的血浆生物标记物的成分。在各种细胞系的上清液和脑脊液(CSF)中检测到了 Aβ-6/-3-40 肽,ADAMTS4 酶的活性促进了 Aβ-6/-3-x 肽的释放。此外,通过免疫组织化学方法,一部分AD病例显示出N端拉长的Aβ-6/-3-x肽在细胞外和血管内定位的证据:讨论:目前的研究结果表明,ADAMTS4与Aβ肽聚集的病理过程和AD淀粉样病理的早期检测都有关联。
Amino-terminally elongated Aβ peptides are generated by the secreted metalloprotease ADAMTS4 and deposit in a subset of Alzheimer's disease brains.
Aims: The aggregation and deposition of amyloid-β (Aβ) peptides in the brain is thought to be the initial driver in the pathogenesis of Alzheimer's disease (AD). Aside from full-length Aβ peptides starting with an aspartate residue in position 1, both N-terminally truncated and elongated Aβ peptides are produced by various proteases from the amyloid precursor protein (APP) and have been detected in brain tissues and body fluids. Recently, we demonstrated that the particularly abundant N-terminally truncated Aβ4-x peptides are generated by ADAMTS4, a secreted metalloprotease that is exclusively expressed in the oligodendrocyte cell population. In this study, we investigated whether ADAMTS4 might also be involved in the generation of N-terminally elongated Aβ peptides.
Methods: We used cell-free and cell-based assays in combination with matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF) and electrochemiluminescence sandwich immunoassays to identify and quantify N-terminally elongated Aβ peptide variants. Antibodies against these Aβ variants were characterised by peptide microarrays and employed for the immunohistochemical analyses of human brain samples.
Results: In this study, we discovered additional ADAMTS4 cleavage sites in APP. These were located N-terminal to Asp-(1) in the Aβ peptide sequence between residues Glu-(-7) and Ile-(-6) as well as Glu-(-4) and Val-(-3), resulting in the release of N-terminally elongated Aβ-6-x and Aβ-3-x peptides, of which the latter serve as a component in a promising Aβ-based plasma biomarker. Aβ-6/-3-40 peptides were detected in supernatants of various cell lines and in the cerebrospinal fluid (CSF), and ADAMTS4 enzyme activity promoted the release of Aβ-6/-3-x peptides. Furthermore, by immunohistochemistry, a subset of AD cases displayed evidence of extracellular and vascular localization of N-terminally elongated Aβ-6/-3-x peptides.
Discussion: The current findings implicate ADAMTS4 in both the pathological process of Aβ peptide aggregation and in the early detection of amyloid pathology in AD.
期刊介绍:
Neuropathology and Applied Neurobiology is an international journal for the publication of original papers, both clinical and experimental, on problems and pathological processes in neuropathology and muscle disease. Established in 1974, this reputable and well respected journal is an international journal sponsored by the British Neuropathological Society, one of the world leading societies for Neuropathology, pioneering research and scientific endeavour with a global membership base. Additionally members of the British Neuropathological Society get 50% off the cost of print colour on acceptance of their article.